Verici Dx plc

LSE VRCI.L

Verici Dx plc Capital Expenditure for the year ending December 31, 2023: USD -231.00 K

Verici Dx plc Capital Expenditure is USD -231.00 K for the year ending December 31, 2023, a 82.34% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Verici Dx plc Capital Expenditure for the year ending December 31, 2022 was USD -1.31 M, a -35.42% change year over year.
Verici Dx plc Capital Expenditure for the year ending December 31, 2021 was USD -965.86 K, a -2,390.80% change year over year.
Verici Dx plc Capital Expenditure for the year ending December 31, 2020 was USD -38.78 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

LSE: VRCI.L

Verici Dx plc

CEO	Ms. Sara jane Barrington A.C.A., A.C.I.M.
IPO Date	Nov. 3, 2020
Location	United Kingdom
Headquarters	Avon House
Employees	19
Sector	Healthcare
Industries Biotechnology Clinical Trials Fintech

Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

Key trends

Past 5 years